Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD)

NCT01202812 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT01202812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01202812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD)
Lead sponsor
Thomas Jefferson University
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2010
Completion date
March 31, 2012
Enrollment
48 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hemoglobin s beta-0 thalassemia, hemoglobin ss, inflammation, quality of life, sickle cell disease